Category C Potential Bioterrorism Agents and Emerging Pathogens

Infectious Disease Clinics of North America

Volumn 20, Issue 2, 2006, Pages 423-441

  Mushtaq, Adnan ^a   El Azizi, Mohamed ^a   Khardori, Nancy ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIVIRUS AGENT; CHLOROFORM; CIDOFOVIR; CORTICOSTEROID; DISINFECTANT AGENT; GLUTARALDEHYDE; HYPOCHLORITE SODIUM; IMMUNOGLOBULIN; INFLUENZA VACCINE; ISONIAZID; LIVE VACCINE; LOPINAVIR PLUS RITONAVIR; OSELTAMIVIR; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; RIFAMPICIN; VACCINIA VACCINE; VIRUS VACCINE; ZANAMIVIR;

AVIAN INFLUENZA; AVIAN INFLUENZA VIRUS; BACTERIAL INFECTION; BIOENGINEERING; BIOLOGICAL WARFARE; BIOTECHNOLOGY; DISINFECTION; EARLY DIAGNOSIS; FEVER; HANTAVIRUS; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS; LABORATORY DIAGNOSIS; MONKEYPOX VIRUS; MYCOBACTERIUM TUBERCULOSIS; NIPAH VIRUS; NONHUMAN; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SYMPTOMATOLOGY; TICK BORNE ENCEPHALITIS; TICK BORNE ENCEPHALITIS FLAVIVIRUS; TICK BORNE HEMORRHAGIC FEVER VIRUS; TRANSGENIC ORGANISM; TUBERCULOSIS; VIRUS ENCEPHALITIS; VIRUS INFECTION; VIRUS STRAIN; VIRUS TRANSMISSION; WEAPON; WEST NILE FLAVIVIRUS; YELLOW FEVER FLAVIVIRUS;

ANIMALS; BIOTERRORISM; HUMANS; VIRUS DISEASES;

EID: 33744511624     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2006.03.003     Document Type: Review

References (105)

1. Beeching N.J., Dance D.A., Miller A.R., et al. Biological warfare and bioterrorism. BMJ 324 (2002) 336-339
2. Christopher G.W., Cieslak T.J., Pavlin J.A., et al. Biological warfare: a historical perspective. JAMA 278 (1997) 412-417
3. Eitzen E.M., and Takafuji E.T. Historical overview of biological warfare. In: Sidell F.R., Takafuji E.T., and Franz D.R. (Eds). Medical aspects of chemical and biological warfare (1997), Borden Institute, Washington, DC 415-423
4. Relman D.A., and Olson J.E. Bioterrorism preparedness: what practitioners need to know?. Infect Med 18 (2001) 497-514
5. Tucker J.B. Historical trends related to bioterrorism: an empirical analysis. Emerg Infect Dis 5 (1999) 498-504
6. Moran G.J. Threats in bioterrorism: II. CDC category B and C agents. Emerg Med Clin N Am 20 (2002) 311-330
7. Centers for Disease Control and Prevention (CDC). Bioterrorism agents/diseases. Available at: http://www.bt.cdc.gov/agent/agentlist-category.asp. Accessed January 5, 2006.
8. Centers for Disease Control and Prevention (CDC). Update: outbreak of Nipah virus-Malaysia and Singapore. MMWR Morb Mortal Wkly Rep 48 (1999) 335-337
9. Lim C.C., Sitoh Y.Y., Lee K.E., et al. Meningoencephalitis caused by a novel paramyxovirus: an advanced MRI case report in an emerging disease. Singapore Med J 40 (1999) 356-358
10. Paton N.I., Leo Y.S., Zaki S.R., et al. Outbreak of Nipah-virus infection among abattoir workers in Singapore. Lancet 354 (1999) 1253-1256
11. Tambyah P.A. The Nipah virus outbreak-a reminder. Singapore Med J 40 (1999) 329-330
12. Chua K.B., Bellini W.J., Rota P.A., et al. Nipah virus: a recently emergent deadly paramyxovirus. Science 288 (2000) 1432-1435
13. Chua K.B., Goh K.J., Wong K.T., et al. Fatal encephalitis due to Nipah virus among pig farmers in Malaysia. Lancet 354 (1999) 1257-1259
14. Amal N.M., Lye M.S., Ksiazek T.G., et al. Risk factors for Nipah virus transmission, Port Dickson, Negeri Sembilan, Malaysia: results from a hospital-based case-control study. Southeast Asian J Trop Med Public Health 31 (2000) 301-306
15. Enserink M. Emerging diseases: Malaysian researchers trace Nipah virus outbreak to bats. Science 289 (2000) 518-519
16. Daniels P., Ksiazek T., and Eaton B.T. Laboratory diagnosis of Nipah and Hendra virus infections. Microbes Infect 3 (2001) 289-295
17. Food and Agriculture Organization of the United Nations Regional Office for Asia and the Pacific Animal Production and Health Commission for Asia and the Pacific (APHCA). Manual on the diagnosis of Nipah virus infection in animals. Thailand: Food and Agriculture Organization of the United Nations. RAP publication no. 2002/01. 2002; p. 29-37.
18. Chong H.T., Kamarulzaman A., Tan C.T., et al. Treatment of acute Nipah encephalitis with ribavirin. Ann Neurol 49 (2001) 810-813
19. Elliott R.M., Schmaljohn C.S., and Collett M.S. Bunyavirus genome structure and gene expression. Curr Top Microbiol Immunol 169 (1991) 91-141
20. Nichol S.T., Spiropoulou C.F., Morzunov S., et al. Genetic identification of a Hantavirus associated with an outbreak of acute respiratory illness. Science 262 (1993) 914-917
21. Childs J.E., Ksiazek T.G., Spiropoulou C.F., et al. Serologic and genetic identification of Peromyscus maniculatus as the primary rodent reservoir for a new Hantavirus in the southwestern United States. J Infect Dis 169 (1994) 1271-1280
22. Duchin J.S., Koster F.T., Peters C.J., et al. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. N Engl J Med 330 (1994) 949-955
23. Centers for Disease Control and Prevention (CDC). Hantavirus pulmonary syndrome-United States: updated recommendations for risk reduction. MMWR Morb Mortal Wkly Rep 51 RR09 (2002) 1-12
24. Song J.-W., Baek L.-J., Gajdusek D.C., et al. Isolation of pathogenic hantavirus from white-footed mouse (Peromyscus leucopus). Lancet 344 (1994) 1637
25. Rollin P.E., Ksiazek T.G., Elliott L.H., et al. Isolation of Black Creek Canal virus, a new Hantavirus from Sigmodon hispidus in Florida. J Med Virol 46 (1995) 35-39
26. Ksiazek T.G., Nichol S.T., Mills J.N., et al. Isolation, genetic diversity, and geographic distribution of Bayou virus (Bunyaviridae: Hantavirus). Am J Trop Med Hyg 57 (1997) 445-448
27. Peters C.J., Mills J.N., Spiropoulou C., et al. Hantavirus infections. In: Guerrant R.L., Walker D.H., and Weller P.F. (Eds). Tropical infectious diseases: principles, pathogens, and practice (1999), Churchill Livingstone, Philadelphia 1217-1235
28. Tsai T.F. Hemorrhagic fever with renal syndrome: mode of transmission to humans. Lab Anim Sci 37 (1987) 428-430
29. Centers for Diseases Control and Prevention (CDC). Yellow fever vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 51 RR17 (2002) 1-10
30. World Health Organization. District guidelines for yellow fever surveillance. Publication no. (WHO/EPI/GEN) 98.09 (1998), WHO, Geneva. http://www.who.int/emc-documents/yellow_fever/whoepigen9809c.html Available at:
31. World Health Organization (WHO). Endemic and pandemic alert response-yellow fever. Available at: http://www.who.int/mediacentre/factsheets/fs100/en/. Accessed January 12, 2006.
32. Monath T.P. Yellow fever. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 3rd edition (1999), Saunders, Philadelphia 815-879
33. Centers for Disease Control and Prevention (CDC). Fatal yellow fever in a traveler returning from Amazonas, Brazil. MMWR Morb Mortal Wkly Rep 51 (2002) 324-325
34. Smithburn K.C., Durieux C., Koerber R., et al. Yellow fever vaccination. WHO monograph series no. 30 (1956), World Health Organization, Geneva
35. Dumpis U., Crook D., and Oksi J. Tick-borne encephalitis. Clin Infect Dis 28 (1999) 882-890
36. Gritsun T.S., Lashkevich V.A., and Gould E.A. Tick-borne encephalitis. Antiviral Res 57 (2003) 129-146
37. Lademann M., Wild B., and Reisinger E.C. Tick-borne encephalitis (FSME)-how great is the danger really?. MMW Fortschr Med 145 (2003) 47-49
38. Centers for Diseases Control and Prevention (CDC). Tick-borne encephalitis. Available at: http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/TBE.htm. Accessed December 20, 2005.
39. Haglund M., and Gunther G. Tick-borne encephalitis-pathogenesis, clinical course and long-term follow-up. Vaccine 21 Suppl 1 (2003) S11-S18
40. Kondrusik M., and Hermanowska-Szpakowicz T. Tick-borne encephalitis: clinical, pathological aspects and sequelae. Neurol Neurochir Pol 38 Suppl 1 (2004) S67-S70
41. Charrel R.N., Attoui H., Butenko A.M., et al. Tick-borne virus diseases of human interest in Europe. Clin Microbiol Infect 10 (2004) 1040-1055
42. Centers for Diseases Control and Prevention (CDC). Crimean-Congo hemorrhagic fever. Available at: http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/cchf.htm. Accessed January 24, 2006.
43. World Health Organization (WHO). Crimean-Congo haemorrhagic fever. Available at: http://www.who.int/mediacentre/factsheets/fs208/en/. Accessed January 24, 2006.
44. Burney M.I., Ghafoor A., Saleen M., et al. Nosocomial outbreak of viral hemorrhagic fever caused by Crimean hemorrhagic fever-Congo virus in Pakistan, January 1976. Am J Trop Med Hyg 29 (1980) 941-947
45. Weber D.J., and Rutala W.A. Risks and prevention of nosocomial transmission of rare zoonotic diseases. Clin Infect Dis 32 (2001) 446-456
46. Swanepoel R., Shepherd A.J., Leman P.A., et al. A common-source outbreak of Crimean-Congo haemorrhagic fever on a dairy farm. S Afr Med J 68 (1985) 635-637
47. Drosten C., Gottig S., Schilling S., et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol 40 (2002) 2323-2330
48. Papa A., Bozovi B., Pavlidou V., et al. Genetic detection and isolation of Crimean-Congo hemorrhagic fever virus, Kosovo, Yugoslavia. Emerg Infect Dis 8 (2002) 852-854
49. Watts D.M., Ussery M.A., Nash D., et al. Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. Am J Trop Med Hyg 41 (1989) 581-585
50. World Health Organization (WHO). Drug and multidrug-resistant tuberculosis. Available at: http://www.who.int/tb/dots/dotsplus/faq/en/. Accessed January 5, 2006.
51. Centers for Disease Control and Prevention (CDC). Reported Tuberculosis in the US, 2003. Available at: http://www.cdc.gov/nchstp/tb/surv/surv2003/default.htm. Accessed January 5, 2006.
52. Fleming D. Influenza pandemic and avian flu. BMJ 331 (2005) 1066-1069
53. Macfarlane J.T., and Lim W.S. Bird flu and pandemic flu. BMJ 331 (2005) 975-976
54. World Health Organization (WHO). Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. Available at: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2006_01_30/en/index.html. Accessed January 7, 2006.
55. Capua I., and Alexander D.J. Avian influenza and human health. Acta Trop 83 (2002) 1-6
56. Hien T.T., Liem N.T., Dung N.T., et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 350 (2004) 1179-1188
57. Ungchusak K., Auewarakul P., Dowell S.F., et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 352 (2005) 333-340
58. Chan P.K. Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997. Clin Infect Dis 34 Suppl 2 (2002) S58-S64
59. Chotpitayasunondh T., Ungchusak K., Hanshaoworakul W., et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis 11 (2005) 201-209
60. Hien T.T., Liem N.T., Dung N.T., et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 350 (2004) 1179-1188
61. Leneva I.A., Roberts N., Govorkova E.A., et al. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 48 (2000) 101-115
62. Govorkova E.A., Leneva I.A., Goloubeva O.G., et al. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 45 (2001) 2723-2732
63. Moscona A. Oseltamivir resistance-disabling our influenza defenses. N Engl J Med 353 (2005) 2633-2636
64. de Jong M.D., Thanh T.T., Khanh T.H., et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353 (2005) 2667-2672
65. Hayden F.G., Belshe R., Villanueva C., et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 189 (2004) 440-449
66. Welliver R., Monto A.S., Carewicz O., et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 285 (2001) 748-754
67. Ksiazek T.G., Erdman D., Goldsmith C.S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348 (2003) 1953-1966
68. Kuiken T., Fouchier R.A.M., Schutten M., et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362 (2003) 263-270
69. World Health Organization (WHO). Available at: www.wpro.who.int/sars/docs/update/update_07022004.asp. Accessed January 7, 2006.
70. Centers for Disease Control and Prevention (CDC). Available at: www.cdc.gov/ncidod/sars/situation.htm. Accessed January 7, 2006.
71. Guan Y., Zheng B.J., He Y.Q., et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302 (2003) 276-278
72. Christian M.D., Poutanen S.M., Loutfy M.R., et al. Severe acute respiratory syndrome. Clin Infect Dis 38 (2004) 1420-1427
73. Booth T.F., Kournikakis B., Bastien N., et al. Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis 191 (2005) 1472-1477
74. Yu I.T.S., Wong T.W., Chiu Y.L., et al. Temporal-spatial analysis of severe acute respiratory syndrome among hospital inpatients. Clin Infect Dis 40 (2005) 1237-1243
75. Seto W.H., Tsang D., Yung R.W., et al. Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). Lancet 361 (2003) 1519-1520
76. Jiang S.S., Chen T., Yang J., et al. Sensitive and quantitative detection of severe acute respiratory syndrome coronavirus infection by real-time nested polymerase chain reaction. Clin Infect Dis 38 (2004) 293-296
77. Chu C.M., Cheng V.C., Hung I.F., et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59 (2004) 252-256
78. Groneberg D.A., Poutanen S.M., Low D.E., et al. Treatment and vaccines for severe acute respiratory syndrome. Lancet Infect Dis 5 (2005) 147-155
79. Tsang K.W., Ho P.L., Ooi G.C., et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348 (2003) 1977-1985
80. Ho J.C., Ooi G.C., Mok T.Y., et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 168 (2003) 1449-1456
81. Stroher U., DiCaro A., Li Y., et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. J Infect Dis 189 (2004) 1164-1167
82. Outbreak of West Nile-like viral encephalitis New York, 1999. MMWR Morb Mortal Wkly Rep 48 (1999) 845-849
83. Update: West Nile-like viral encephalitis-New York, 1999. MMWR Morb Mortal Wkly Rep 48 (1999) 890-892
84. Asnis D.S., Conetta R., Teixeira A.A., et al. The West Nile Virus outbreak of 1999 in New York: the Flushing Hospital experience. Clin Infect Dis 30 (2000) 413-418
85. Lanciotti R.S., Roehrig J.T., Deubel V., et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 286 (1999) 2333-2337
86. Giladi M., Metzkor-Cotter E., Martin D.A., et al. West Nile encephalitis in Israel, 1999: the New York connection. Emerg Infect Dis 7 (2001) 659-661
87. Jia XY, Briese T, Jordan I, et al. Genetic analysis of West Nile New York 1999 encephalitis virus. Lancet 354;1971-2.
88. Pealer L.N., Marfin A.A., Petersen L.R., et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 349 (2003) 1236-1245
89. Detection of West Nile virus in blood donations-United States, 2003. MMWR Morb Mortal Wkly Rep 52 (2003) 769-772
90. Iwamoto M., Jernigan D.B., Guasch A., et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 348 (2003) 2196-2203
91. Diamond M.S., Shrestha B., Mehlhop E., et al. Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus. Viral Immunol 16 (2003) 259-278
92. Sejvar J.J., Haddad M.B., Tierney B.C., et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA 290 (2003) 511-515
93. Parida M., Posadas G., Inoue S., et al. Real-time reverse transcription loop-mediated isothermal amplification for rapid detection of West Nile virus. J Clin Microbiol 42 (2004) 257-263
94. Centers for Diseases Control and Prevention (CDC). Human monkeypox-Kasai Oriental, Democratic Republic of Congo, February 1996-October 1997. MMWR Morb Mortal Wkly Rep 46 (1997) 1168-1171
95. Breman J.G., and Henderson D.A. Poxvirus dilemmas-monkeypox, smallpox. N Engl J Med 339 (1998) 556-559
96. Centers for Disease Control and Prevention. Multistate outbreak of monkeypox-Illinois, Indiana, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep 52 (2003) 537-540
97. Centers for Disease Control and Prevention. Update: multistate outbreak of monkeypox-Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep 52 (2003) 561-564
98. Centers for Disease Control and Prevention. Update: multistate outbreak of monkeypox-Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep 52 (2003) 642-646
99. Human monkeypox and other poxvirus infections of man. In: Fenner F., Henderson D.A., Arita I., et al. (Eds). Smallpox and its eradication, vol. 29 (1988), World Health Organization, Geneva 1287-1319
100. Nalca A., Rimoin A.W., Bavari S., et al. Reemergence of Monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis 41 (2005) 1765-1771
101. Damon I.K., and Esposito J.J. Poxviruses that infect humans. In: Murray P.R., Baron E.J., Jorgensen J.H., et al. (Eds). Manual of clinical microbiology. 8th edition (2003), ASM Press, Washington, DC 1583-1591
102. Baker R.O., Bray M., and Huggins J.W. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res 57 (2003) 13-23
103. Fine P.E., Jezek Z., Grab B., et al. The transmission potential of monkeypox virus in human populations. Int J Epidemiol 17 (1988) 643-650
104. Arita I., Jezek Z., Khodakevich L., et al. Human monkeypox: a newly emerged orthopoxvirus zoonosis in the tropical rain forests of Africa. Am J Trop Med Hyg 34 (1985) 781-789
105. Petro J.B., Plasse T.R., and McNulty J.A. Biotechnology: impact on biological warfare and biodefense. Biosecurity and Bioterrorism: Biodefense Strategy, Practice and Science 1 (2003) 161-168